doi: 10.1097/QAD.0b013e3283402bc1.
Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients
Affiliations
- PMID: 20962616
- DOI: 10.1097/QAD.0b013e3283402bc1
Item in Clipboard
Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients
AIDS.
.
Abstract
Immune changes induced by the CCR5 antagonist maraviroc raise the question of an impairment of responses to vaccines. We evaluated the immunogenicity of the adjuvanted pandemic influenza A-H1N1v 2009 vaccine in HIV-1-infected patients with suppressed HIV viremia with or without a maraviroc-containing regimen. Seroprotection, seroconversion, and geometric mean titer ratio of specific antibody titers did not differ between groups. These results suggest that maraviroc does not significantly affect the immune response to this adjuvanted vaccine.
Similar articles
-
Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.Vaccine. 2011 Feb 11;29(8):1677-82. doi: 10.1016/j.vaccine.2010.12.047. Epub 2011 Jan 1. Vaccine. 2011. PMID: 21199699 Clinical Trial.
-
Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.Vaccine. 2011 Nov 15;29(49):9209-13. doi: 10.1016/j.vaccine.2011.09.103. Epub 2011 Oct 3. Vaccine. 2011. PMID: 21974995
-
Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.Biologicals. 2012 Mar;40(2):134-9. doi: 10.1016/j.biologicals.2011.12.001. Epub 2012 Jan 20. Biologicals. 2012. PMID: 22261282 Clinical Trial.
-
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients.Vaccine. 2011 Apr 5;29(16):2836-9. doi: 10.1016/j.vaccine.2011.02.020. Epub 2011 Feb 22. Vaccine. 2011. PMID: 21349364
-
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.Vaccine. 2010 Feb 17;28(7):1740-5. doi: 10.1016/j.vaccine.2009.12.014. Epub 2009 Dec 22. Vaccine. 2010. PMID: 20034605 Clinical Trial.
Cited by
-
Persistent immune activation in chronic HIV infection: do any interventions work?AIDS. 2013 May 15;27(8):1199-208. doi: 10.1097/QAD.0b013e32835ecb8b. AIDS. 2013. PMID: 23324661 Free PMC article. No abstract available.
-
CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.Mol Med. 2012 Oct 24;18(1):1240-8. doi: 10.2119/molmed.2012.00206. Mol Med. 2012. PMID: 22875102 Free PMC article. Clinical Trial.
-
Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction.Viruses. 2016 Sep 29;8(10):269. doi: 10.3390/v8100269. Viruses. 2016. PMID: 27690086 Free PMC article. Review.
-
Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.PLoS One. 2014 Jan 27;9(1):e87334. doi: 10.1371/journal.pone.0087334. eCollection 2014. PLoS One. 2014. PMID: 24475275 Free PMC article. Clinical Trial.
-
Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective.PLoS One. 2011;6(12):e29249. doi: 10.1371/journal.pone.0029249. Epub 2011 Dec 22. PLoS One. 2011. PMID: 22216224 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
